Ropeginterferon for MDS/MPN and CMML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a study drug called ropeginterferon alfa-2b for people with certain blood cancers like CMML and MDS/MPN overlap syndromes. The goal is to see if it can help control the disease with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of CMML or a related MDS/MPN overlap syndrome.
- Your platelet count must be above 50,000 and your white blood cell count above 1,000.
- You need to be in fairly good health (able to do daily activities with some help).
- You cannot have had prior treatment with interferon or azacitidine.
- You must not have severe depression, eye problems, or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies ropeginterferon alfa-2b (a type of interferon medicine) in adults with early, lower-risk myelofibrosis. The goal is to see if it can control the disease better or improve outcomes with an acceptable safety profile.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This study tests whether adding a type of interferon (ropeginterferon) to your current myelofibrosis treatment (ruxolitinib) is safe and tolerable. Myelofibrosis is a blood disorder where bone marrow becomes scarred; this combination might help control the disease better.
This trial tests a combination of two drugs—ropeginterferon (an immune-boosting protein) and azacitidine (a cancer-fighting medicine)—in adults newly diagnosed with myelodysplastic syndrome or acute myeloid leukemia who have a specific genetic change (TP53 mutation). The goal is to help patients who cannot tolerate intensive chemotherapy.
This trial tests whether the drug ropeginterferon can help people with a JAK2 gene mutation who have additional risk factors but do not yet have a blood cancer. The goal is to see if treatment can prevent blood clots, high blood counts, or other complications.
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
Hear when a new Atypical Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.